Short answer
CapsoVision, Inc (CV) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 results released for quarter ended September 30, 2026.
CapsoVision, Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results released for quarter ended September 30, 2026
- Exhibit 99.1 contains CapsoVision’s detailed financial results and management commentary
- Investors should review the exhibit for revenue, profitability, cash flow and outlook implications
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $3.568M, up from $3.538M, while gross margin fell to 49% from 54%
- Net loss narrowed to $7.339M, or $0.15 per share, from $7.921M, or $0.17
- AI Highlights FDA-cleared and launched November 2, creating a potential 2027 growth catalyst for CapsoCam Plus
- CapsoCam Plus patients reached 184,000, up from 151,000 year over year
- Financing added $17.8M net from a registered direct offering and $1.7M through ATM sales, supporting cash of $21.757M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CapsoVision, Inc 8-K filings
Get the next CV 8-K as it lands
Follow CV for push alerts, or ask the research agent what this filing means.